Stryker (NYSE:SYK) Stock Gets Price Target Reduction from Citigroup

Stryker (NYSE:SYK) had its price target lowered by investment analysts at Citigroup from $360.00 to $315.00 in a research report issued on Friday, Benzinga reports. The firm currently has a “buy” rating on the medical technology company’s stock. Citigroup‘s target price would indicate a potential upside of 8.04% from the stock’s current price.

Other analysts have also issued research reports about the company. BTIG Research decreased their price objective on Stryker from $316.00 to $304.00 and set a “buy” rating on the stock in a research note on Friday. Argus set a $370.00 target price on shares of Stryker in a research note on Thursday, July 9th. Piper Sandler reduced their target price on shares of Stryker from $420.00 to $390.00 and set an “overweight” rating on the stock in a report on Friday, July 31st. Wall Street Zen cut shares of Stryker from a “buy” rating to a “hold” rating in a research note on Saturday, October 3rd. Finally, Needham & Company LLC lowered their price target on shares of Stryker from $418.00 to $359.00 and set a “buy” rating for the company in a report on Friday. Seventeen investment analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $355.84.

Stryker Price Performance

Shares of Stryker stock traded down $20.19 during trading on Friday, hitting $291.56. 6,437,706 shares of the company were exchanged, compared to its average volume of 2,473,643. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. Stryker has a fifty-two week low of $267.00 and a fifty-two week high of $389.33. The stock has a market capitalization of $111.83 billion, a price-to-earnings ratio of 30.21, a P/E/G ratio of 1.96 and a beta of 0.78. The firm has a 50 day moving average price of $293.56 and a 200 day moving average price of $324.86.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, October 29th. The medical technology company reported $3.52 EPS for the quarter, missing analysts’ consensus estimates of $3.55 by ($0.03). The company had revenue of $6.52 billion for the quarter, compared to analyst estimates of $6.62 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. Stryker’s quarterly revenue was up 7.6% compared to the same quarter last year. During the same quarter last year, the company posted $3.19 EPS. On average, equities analysts expect that Stryker will post 14.93 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Stryker news, insider Dylan Crotty sold 441 shares of the firm’s stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $328.61, for a total value of $144,917.01. Following the sale, the insider directly owned 6,102 shares of the company’s stock, valued at approximately $2,005,178.22. This trade represents a 6.74% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Ronda Stryker sold 300,000 shares of Stryker stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $335.90, for a total value of $100,770,000.00. Following the completion of the sale, the director owned 2,301,375 shares of the company’s stock, valued at $773,031,862.50. This trade represents a 11.53% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 351,267 shares of company stock worth $118,197,701. 4.60% of the stock is owned by company insiders.

Institutional Investors Weigh In On Stryker

A number of institutional investors have recently bought and sold shares of SYK. AIA Group Ltd boosted its stake in Stryker by 230.4% during the 3rd quarter. AIA Group Ltd now owns 46,593 shares of the medical technology company’s stock valued at $12,831,000 after acquiring an additional 32,493 shares during the last quarter. Provenance Wealth Advisors LLC increased its position in shares of Stryker by 1,376.5% in the 3rd quarter. Provenance Wealth Advisors LLC now owns 3,455 shares of the medical technology company’s stock worth $951,000 after purchasing an additional 3,221 shares during the last quarter. Associated Banc Corp bought a new stake in shares of Stryker in the 3rd quarter worth about $5,488,000. Integrity Alliance LLC. increased its position in shares of Stryker by 14.7% in the 3rd quarter. Integrity Alliance LLC. now owns 2,313 shares of the medical technology company’s stock worth $637,000 after purchasing an additional 296 shares during the last quarter. Finally, Integrity Advisory Solutions LLC raised its stake in shares of Stryker by 24.0% in the 3rd quarter. Integrity Advisory Solutions LLC now owns 1,282 shares of the medical technology company’s stock valued at $353,000 after purchasing an additional 248 shares in the last quarter. 77.09% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Stryker

Here are the key news stories impacting Stryker this week:

• Positive Sentiment: Analysts remain broadly constructive despite lowering estimates. RBC, Barclays, Citizens JMP and BTIG reduced their price targets but maintained Outperform, Overweight, Market Outperform or Buy ratings, indicating potential upside from recent levels. RBC price target article
• Neutral Sentiment: Third-quarter revenue increased 7.6% year over year to $6.52 billion, while adjusted EPS rose to $3.52 from $3.19. Management highlighted strength in MedSurg, margin improvement and continued investment in robotic surgery, but those positives were overshadowed by weaker areas of the business. Stryker third-quarter results
• Negative Sentiment: Stryker missed Wall Street expectations, reporting $3.52 in EPS versus approximately $3.55–$3.56 expected and $6.52 billion in revenue versus about $6.62 billion expected. The company also cut its 2026 forecast to 6.5%–7.0% organic sales growth and $14.80–$14.90 in adjusted EPS, down from prior guidance of 8.3%–9.3% sales growth and $14.95–$15.10 EPS. Stryker earnings and revenue miss
• Negative Sentiment: Investors remain concerned that weaker joint-replacement demand, supply disruptions and a previously unresolved manufacturing issue affecting peripheral vascular products could pressure sales into 2027. The disclosure has prompted scrutiny of the company’s execution, particularly as a new CEO takes over. Stryker peripheral vascular problems
• Negative Sentiment: Canaccord downgraded Stryker from Buy to Hold and cut its price target from $385 to $300, reinforcing concerns that the guidance reduction reflects more than a temporary earnings setback. Canaccord Stryker rating

Stryker Company Profile

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company’s product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.